Similar results were observed with Canagliflozin in CREDENCE trial, which included diabetic patients with CKD [217], as well as in a post hoc analysis of the DELIGHT trial with similar cohorts of patients where Dapagliflozin, along as earlier results, also produced an increase in erythropoietin to a mean of 82.9 pg/mL, compared to placebo (79.8 pg/mL) [218]. This evidence concerns the gene EPO and chronic kidney disease.